Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's Resolute Integrity

This article was originally published in The Gray Sheet

Executive Summary

Firm announces CE mark clearance and international roll-out of its Resolute Integrity zotarolimus-eluting coronary stent system on Aug. 30. Shipments will start the week of Sept. 6. The device incorporates the MicroTrac delivery system and continuous sinusoid technology to offer improved deliverability and conformability while retaining the same drug and BioLinx polymer of the original Resolute drug-eluting stent, the firm explains. Continuous sinusoid technology enables the stent to be made from a single wire. Medtronic notes it also will pursue U.S. approval
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT029347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel